Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Depression and renal disease.

Eliana Tossani1, Paolo Cassano, Maurizio Fava

  • 1Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.

Seminars in Dialysis
|March 18, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Feasibility and acceptability of a guided internet-based acceptance and commitment therapy intervention (MobACT) for adults with chronic pain in Italy: A pilot mixed-methods randomized controlled trial.

Internet interventions·2026
Same author

Validation of the Italian Multidimensional Psychological Flexibility Inventory Short Form (MPFI-24).

Behavioral sciences (Basel, Switzerland)·2026
Same author

Applying Ecological Momentary Assessment (EMA) to Understand Overweight and Obesity: A Systematic Review.

Journal of personalized medicine·2025
Same author

The mediating role of protective factors in relationship between caregiving components and psychosocial adjustment among young carers: a meta-analysis.

Psychology & health·2025
Same author

Italian validation of the Orbach and Mikulincer Mental Pain Scale-8 (OMMP-8).

Annals of general psychiatry·2025
Same author

Youth benefit finding and caregiving in a parental illness context: a latent profile analysis.

Frontiers in psychology·2025

Major depressive disorder (MDD) significantly impacts patients with kidney disease, increasing morbidity and mortality. Treating depression in renal failure improves outcomes and medication adherence, with safety considerations for antidepressant selection.

Area of Science:

  • Nephrology
  • Psychiatry
  • Clinical Pharmacology

Background:

  • Major depressive disorder (MDD) is highly prevalent and often chronic, frequently co-occurring with other medical conditions.
  • MDD exacerbates the prognosis, quality of life, and treatment adherence in patients with comorbid illnesses, including kidney disease.
  • Depression in renal failure patients increases both morbidity and mortality, negatively impacting overall patient outcomes.

Purpose of the Study:

  • To evaluate the impact of treating depressive symptoms in patients with renal failure.
  • To assess the safety and efficacy of antidepressant treatment in individuals with kidney disease.
  • To highlight the importance of careful antidepressant selection and dosing in this population.

Main Methods:

  • The study reviews existing literature on MDD in patients with renal failure.

Related Experiment Videos

  • It discusses the risks of untreated depression versus the benefits and safety considerations of antidepressant pharmacotherapy.
  • Emphasis is placed on selecting antidepressants with low volume of distribution and protein binding, and initiating treatment at low doses.

    • Main Results:

    • Treatment of depressive symptoms in renal failure patients can improve medication acceptability and overall patient outcomes.
    • Antidepressant therapy is considered safe in renal failure patients when specific pharmacokinetic properties are considered.
    • Screening for cytochrome P450 (CYP) isoenzyme interactions is recommended before initiating treatment.

    Conclusions:

    • Addressing depression in patients with kidney disease is crucial for improving their health outcomes.
    • Careful selection of antidepressants, focusing on low volume of distribution, low protein binding, and low initial doses, can mitigate safety concerns.
    • Pharmacokinetic screening for drug interactions is essential for safe and effective antidepressant treatment in renal failure.